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osting by EAbstract Aim of the study: In the present study, we examined and compared the effect of Poly-
herbal (PH), Allopolyherbal-A (APH-A), Allopolyherbal-B (APH-B), and Allopolyherbal-C
(APH-C) formulations on hyperglycemia, lipid proﬁle, renal, and hepatic function in streptozotocin
(STZ) induced diabetes mellitus in rats.
Materials and methods: The hypoglycemic activity (along with other parameters) of Polyherbal and
Allopolyherbal formulations was investigated in STZ induced diabetes in rats. Polyherbal (PH)
(3.63 g/kg body wt.); Allopolyherbal-A (APH-A) [(5 mg Gliclazide + 1.81 g PH)/kg body wt.];
Allopolyherbal-B (APH-B) [(4 mg Gliclazide + 2.17 g of PH)/kg body wt.]; Allopolyherbal-C
(APH-C) [(2 mg of Gliclazide + 2.904 g of PH)/kg body wt.], and Gliclazide (10 mg/kg body wt.)
were administered once a day, orally by gavages for 21 days.
Blood glucose levels were measured on 0, 7, 14, and 21 days of the study; total cholesterol, triglyc-
erides, LDL, VLDL, HDL, serum creatinine, SGOT, and SGPT were estimated on 21st day.784580219 (R. Kumar), +91
(R. Kumar), draroravimal@
f Diabetes Mellitus. Published
lsevier
R. Kumar et al.46Results: Gliclazide, Polyherbal (PH), Allopolyherbal-A (APH-A), Allopolyherbal-B (APH-B), and
Allopolyherbal-C (APH-C) formulations treated rats showed signiﬁcant (P< 0.01) decrease in
blood glucose, total cholesterol, triglycerides, LDL, VLDL, serum creatinine, SGOT, and SGPT
level, along with signiﬁcant increase in HDL.
Conclusions: Present ﬁndings provide experimental evidence that the combination of allopathic
hypoglycemic drugs with hypoglycemic Polyherbal formulations provides effective and rapid glyce-
mic control and can also minimize the cardiovascular risk factors of type II diabetes mellitus.
 2011 International Journal of Diabetes Mellitus. Published by Elsevier Ltd. All rights reserved.1. Introduction
Diabetes mellitus is characterized by hyperglycemia, hypercho-
lesterolemia, and hypertriglyceridemia, resulting from defects
in insulin secretion or reduced sensitivity of the tissue to insulin
(insulin resistance) and/or combination of both [1]. The world-
wide survey reported that the diabetes is affecting nearly 10%
of the population [2]. It is the third leading cause of death
(after heart disease and cancer) in many developed countries.
It is a serious endocrine syndrome with poor metabolic con-
trol and responsible for increased risk of cardiovascular dis-
eases including atherosclerosis, renal failure, blindness or
diabetic cataract worldwide [3,4]. Therapeutic options for dia-
betes are diet, exercise, oral hypoglycemic drugs, and insulin
therapy.
Treatment with oral hypoglycemic agents is associated with
side effects related to pharmacokinetic properties, secondary
failure rates, hypoglycemia, gastrointestinal disturbances, skin
reactions, hematological disorders, and rise in hepatic enzyme
level.
Management of diabetes without dyslipidemia and side ef-
fects is still a challenge to the medical community. For thou-
sands of years plants and their derivatives are being used for
treatment of diabetes mellitus. Although, herbal medicines
have long been used effectively in treating diseases throughout
the world and frequently considered to be less toxic and free
from side effects as compared to synthetic ones [1,3]. The com-
bination of allopathic and herbal drugs can help to overcome
the resistance to insulin and oral hypoglycemic therapy in case
of uncontrolled diabetes mellitus. The side effects, dyslipide-
mias and dose of allopathic drugs can be reduced by their
use in combination with herbal drugs. One of the examples
of such Allopolyherbal formulation is therapeutic approach
by combination of 4-hydroxyisoleucine and pioglitazone and
combined therapy of 4-hydroxyisoleucine and glyburide [5].
Streptozotocin (STZ) is a naturally occurring nitrosourea
product of Streptomyces achromogenes. Usually, the intraperi-
toneal injection of a single dose (60 mg/kg body weight) of it
exerts direct toxicity on b cells resulting in necrosis within
48–72 h and causes hyperglycemia.
In the present study, leaves and fruit pulp of Aegle marmelos,
leaf pulp of Aloe barbadensis, leaves ofAzadirachta indica, and
seeds of Trigonella foenum graecum in Polyherbal (PH) and in
combination with Gliclazide as Allopolyherbal-A (APH-A),
Allopolyherbal-B (APH-B), and Allopolyherbal-C (APH-C)
formulations were used to investigate their effect on blood glu-
cose, lipid proﬁle, serum creatinine, SGOT, and SGPT in rat
model of STZ induced diabetes mellitus.
A comparison was made with the Gliclazide, a standard
drug used in treatment of diabetes mellitus [6]. Gliclazide is a
sulphonylurea drug which stimulates insulin secretion throughthe beta cell sulphonylurea receptor, and possibly through a
direct effect on intracellular calcium transport. It speciﬁcally
improves the abnormal ﬁrst phase insulin release in type II dia-
betes, and also has an effect on the second phase. It is exten-
sively metabolised, and renal clearance accounts for only 4%
of total drug clearance. This pattern of insulin release is
thought to explain the lower incidence of hypoglycemic epi-
sodes and weight gain compared with some other sulphonylu-
reas. There is also a reduction in hepatic glucose production
and improvement in glucose clearance, without changes in
insulin receptors. This suggests a possible post-receptor effect
on insulin action, perhaps by stimulation of hepatic fructose-
2,6-bisphosphatase and muscle glycogen synthase. Gliclazide
reduces platelet adhesion, aggregation, and hyperactivity and
increases ﬁbrinolysis. These actions, thought to be independent
of its hypoglycemic activity, may make Gliclazide useful in
halting the progression of diabetic microangiopathy [7].
The medicinal uses of plants used in study can be summa-
rized as follows [8]:
Plant name Family Uses
A. marmelos Rutaceae Stomachic, antimicrobial,
antidiarrhoeal, digestive, astringent,
spasmolytic, hypoglycemic
A. barbadensis Liliaceae Purgative, topically emollient,
anti-inﬂammatory, antimicrobial,
hypoglycemic
A. indica Meliaceae Antimicrobial, antifungal,
anthelmintic, antiviral, antipyretic,
antimalarial, spermicidal,
antiinﬂammatory, hypoglycemic
T. foenum
graecum
Papilionaceae Appetizer, demulcent, hypoglycemic2. Materials and methods
Streptozotocin was purchased from Sisco Research Laborato-
ries Pvt. Ltd., Mumbai, India; Gliclazide was purchased from
Nu-Life Laboratories, India. All other chemicals and reagents
used were of analytical grade and purchased from ASSES
Chemicals, Jodhpur, Rajasthan. Glucose, cholesterol, triglyc-
eride, total cholesterol, cholesterol–HDL, serum creatinine,
SGPT, and SGOT kits were purchased from Logotech Delhi
(India) Pvt. Ltd.2.1. Plant material
The medicinal plants were identiﬁed and collected from local
places of Jodhpur in month of August and September,
authenticated by Botanical Survey of India, Jodhpur. A.
Hypoglycemic and hypolipidemic effect of Allopolyherbal formulations 47marmelosNo.: JNU/PH2009 AV A-7; Aloe vera: JNU/PH2009
AV A-4; A. indica No.: JNU/PH2009 AV A-6; T. foenum
graecum: JNU/PH2009 AV A-5.
2.2. Preparation of Polyherbal and Allopolyherbal formulations
The medicinal plant parts like fruits and leaves ofA. marmelos,
and leaves of A. indica were collected from local areas of
Jodhpur, Rajasthan. Leaves of A. vera and seeds of T. foenum
graecum were purchased from market. After drying the respec-
tive part of the plants under shade they were grinded by using
mixer grinder and then sieved by using sieve shaker and man-
ually by passing through 100 no. sieve. The sieved powder was
collected in polyethylene bags. The Polyherbal formulation
was prepared by taking 1/5th of the individual doses of respec-
tive plant part, calculated on the basis of percentage yield and
dose of extract reported earlier (Table 1). The Allopolyherbal
formulations (APH-A, APH-B, APH-C) were prepared by
mixing Polyherbal formulation and Gliclazide in different
experimental ratios (Table 2).
2.3. Animals
Adult Albino rats of Wistar strain (150–200 g) of either sex
were procured from the animal house of Faculty of Pharma-
ceutical Sciences, Jodhpur National University, Jodhpur,
Rajasthan. Animals were provided with standard pellets and
drinking water ad libitum and were maintained at 12 h light
and dark cycle. The protocol of the experiment (IPS/PCOL/
MPH06/002) was approved by Institutional Animal Ethics
Committee (IAEC) of Jodhpur National University and were
conducted in accordance with guidelines as per ‘‘Guide for
the care and use of laboratory animal’’ and with permission
from Committee for the Purpose of Control and Supervision
of Experiments on Animals (CPCSEA).
2.4. Induction of diabetes and experimental design
Streptozotocin was dissolved in 100 mM citrate buffer (pH 4.5)
and calculated amount of the dose (60 mg/kg) of the fresh
solution was injected intraperitoneally to overnight fasted rats.Table 1 Polyherbal dose on the basis of percentage yields of extrac
Plant name (powder) Extract yield (%) Extract dose (mg/kg) E
Trigonella foenum seed 2 [9] 50 [10] 2
Aegle marmelos fruit pulp 2.98 [11] 250 [12] 2
Aegle marmelos leaves 10 [13] 100 [14] 1
Aloe vera leaf pulp 5.64 [15] 300 [16] 5
Azadirachta indica leaf 50.2 [17] 500 [18] 5
Dose of Polyherbal
Table 2 Composition of Allopolyherbal formulations (Gliclazide: P
Allopolyherbal
formulation
% of Gliclazide’s
kg body wt.) (mg)
APH-A 50%= 5
APH-B 40%= 4
APH-C 20%= 2Blood glucose was checked 48 h later and animals showing
blood glucose value more than 250 mg/dl were included in
the experiments and termed as diabetic. Total seven groups
(one non-diabetic and six diabetic) consisting of six animals
in each group were taken and treatments were given orally,
once a day, in the following manner:
Group I: served as control (non-diabetic) and given 1%
gum acacia (1 ml/kg).
Group II: served as positive control and given 1% gum aca-
cia (1 ml/kg).
Group III: administered Gliclazide (10 mg/ml/kg).
Group IV: administered Polyherbal formulation (PH)
(3.63 g/2 ml/kg).
Group V: administered Allopolyherbal-A formulation
(APH-A) [(5 mg of Gliclazide + 1.81 g of PH)/2 ml/kg].
Group VI: administered Allopolyherbal-B formulation
(APH-B) [(4 mg of Gliclazide + 2.17 g of PH)/2 ml/kg].
Group VII: administered Allopolyherbal-C formulation
(APH-C) [(2 mg of Gliclazide + 2.904 g PH)/2 ml/kg].
*Gliclazide, PH, APH-A, APH-B, and APH-C, formulated
into suspension, using 1% gum acacia in distilled water, just
before administration.
2.5. Blood glucose level monitoring
Blood glucose level was estimated using biochemistry ana-
lyzer (GOD POD method) on 0, 7, and 14th day of
experiment, blood samples were taken from retro orbital
plexus.
At the end of study (on 21st day), blood samples were col-
lected by heart puncture from anesthetized (slight exposure to
ether) rats and then after animals were sacriﬁced as per IAEC
guidelines.
2.6. Biochemical analysis
The serum was separated by centrifugation at 3000 rpm for
10 min in microcentrifuge (star 21, India), then various
biochemical parameters: blood glucose level, serum triglycer-t and extract dose.
xtract yield /100 g of powder (g) Dose of powder/kg body wt. (g)
2.5
.98 8.38
0 1
.64 5.31
0.2 0.996
18.2/5 = 3.63
olyherbal).
dose (10 mg/ % of mean dose (3.63 g/kg body wt.)
of plant parts powders (g)
50%= 1.81
60%= 2.17
80%= 2.904
48 R. Kumar et al.ides (TRIGLYCERIDES), high density lipoproteins (HDL),
cholesterol (TOTAL CHOLESTEROL), LDL (low density
lipoprotein), very low density lipoprotein (VLDL), SGPT,
SGOT, and serum creatinine were estimated using biochemis-
try analyzer (model no. Rapid star 21, SEAC, India) using
respective kits.2.7. Statistical analysis
All the data were statistically analyzed for variance and signif-
icance, by one way ANOVA followed by Student’s t-test and
Dunett’s test. All results are expressed as Mean ± SEM and
observed P value is <0.05.3. Results
3.1. Blood glucose
Streptozotocin causes selective destruction of b cells of islets
of pancreas and brings an increase in blood glucose levels. It
is evident from the present investigation that STZ adminis-
tration at the dose of 60 mg/kg body weight causes signiﬁ-
cant diabetogenic response in albino rats (Table 3). Blood
glucose levels were measured randomly on 0, 7th, 14th
and 21st day of study.
Blood glucose levels in diabetic rats were raised nearly to
2.5–3.5-fold as compared to normal control group rats on
starting (0) day. The increase in glucose levels in diabetic con-
trol group was found to be signiﬁcant (P< 0.05) when com-
pared to normal control group.
The raised levels of blood glucose declined sharply after
oral administration of Gliclazide, PH, APH-A, APH-B, and
APH-C. When comparisons were made between ‘0’ day and
21st day of treated groups, there was highly statistically signif-
icant (P< 0.01) (Table 3) decline in blood glucose levels. If de-
cline in blood glucose levels is to be the only indices, then
treatment with PH, APH-A, APH-B, APH-C, and Gliclazide
were highly effective in causing signiﬁcant antihyperglycemic
response in this strain of rats.
As far as the relative efﬁcacy is concerned, though all the
four formulations produced more anti hyperglycemic activity
than Gliclazide, but APH-A has been proven the highest anti-
hyperglycemic activity among all.Table 3 Blood glucose level in control and experimental groups of
Groups Day
Day 0 (mg/dl) Day 7 (mg/dl)
Normal control 108.89 ± 3.80 111.64 ± 2.8
Positive control 258.20 ± 6.73# 252.40 ± 5.0#
Gliclazide 343.60 ± 40.8 256.81 ± 41.3
PH 349.8 ± 43.1 209.2 ± 28.8a
APH-A 390.8 ± 52.0 197.4 ± 29.4a
APH-B 308.3 ± 24.8 126.9 ± 2.0b
APH-C 319.1 ± 32.1 121.9 ± 2.1b
Values are expressed in Mean ± SEM (n= 6 in each group).
# P< 0.05; when positive control compared with normal control (follo
a P< 0.05; when other groups compared with respective ‘0’ day (follo
b P< 0.01; when other groups compared with respective ‘0’ day (follo3.2. Serum: lipids, serum creatinine and hepatic enzymes
On 21st day there was a statistically signiﬁcant (P< 0.05) in-
crease in serum total cholesterol (›54%), triglycerides
(›112%), VLDL (›219%), serum creatinine (›99%), SGPT
(›215%), and SGOT (›172%) and decrease in HDL (ﬂ13%)
of positive control group rats, as compared to normal control
group rats. Treatment with Gliclazide, PH, APH-A, APH-B,
and APH-C for 21 days, signiﬁcantly decreased total choles-
terol, triglycerides, LDL, VLDL, serum creatinine, SGPT,
and SGOT levels when compared to positive control group
(Table 4). There was also highly signiﬁcant (bP< 0.01) in-
crease in serum HDL level by treatment with APH-C com-
pared to positive control group.
As far as the relative efﬁcacy is concerned, though all the
four formulations showed more/comparable activity to
Gliclazide on all the biochemical parameters, but as far as
overall efﬁcacy is concerned for all parameters, APH-A is
the best among all.
3.3. Toxicity study
Since the dose of Allopolyherbal formulations were very high
and did not produce any toxic effects or mortality during study
period as evident from results showing normal hepatic as well
as renal functions, therefore on this basis no separate toxicity
studies were carried out.4. Discussion
In the present study, there was signiﬁcant decrease in the blood
glucose level when STZ induced diabetic rats were treated with
Polyherbal and Allopolyherbal formulations (Table 3).
The previous studies have suggested that the A. marmelos
(fruit and leaves) and T. foenum graecum seed produce hypo-
glycemic effect probably by enhancing the peripheral utiliza-
tion of glucose, correcting the impaired hepatic glycolysis
and limiting its gluconeogenic formation similar to insulin
[19]. A study has also revealed that the A. vera pulp stimulates
insulin secretion from the remnant b-cells [20]. In case of Neem
leaves the probable cause of reduction of blood glucose level
might be due to increased peripheral uptake of glucose and in-
creased sensitivity of insulin receptors [21].rat.
Day 14 (mg/dl) Day 21 (mg/dl)
111.80 ± 3.5 114 ± 2.16
259.20 ± 8.20# 269 ± 11#
193.82 ± 15.13b 138 ± 3.71 (ﬂ59.83%)b
134 ± 2.14b 120.6 ± 2.1 (ﬂ65.52%)b
132.8 ± 2.6b 120.0 ± 2.6 (ﬂ69.29%)b
124.2 ± 2.6b 116.4 ± 2.6 (ﬂ62.24%)b
119.2 ± 4.4b 110.4 ± 4.4 (ﬂ65.40%)b
wed by t-test).
wed by Dunett’s test).
wed by Dunett’s test).
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Hypoglycemic and hypolipidemic effect of Allopolyherbal formulations 49As suggested by the previous studies, the active constituents
like 4-hydroxy isoleucine present in T. foenum graecum seed;
marmelosin and aegeline present in A. marmelos fruit and
leaves; phytosterols present in A. vera leaf pulp; tetra terpe-
noids like nimocinol and isonimocinol present in A. indica
leaves are responsible for the improvement of glycemic and
dyslipidemic conditions of diabetes mellitus in experimental
animals [8,22].
The present study has shown similar results for hypoglyce-
mic activity and other biochemical parameters in accordance
with previous studies.
Allopolyherbal-A formulation (APH-A) showed maximum
effectiveness in decreasing blood glucose levels in the diabetic
rats and proved to have a better plasma glucose lowering effect
than Gliclazide, Polyherbal (PH), Allopolyherbal-B (APH-B)
and Allopolyherbal-C (APH-C) formulations (Table 3).
The level of serum lipids are usually elevated in diabetes
which represents a high risk factor for coronary heart disease.
Under normal circumstances, insulin activates the enzyme lipo-
protein lipase, which hydrolyses triglycerides.However, in a dia-
betic state, lipoprotein lipase is not activated in sufﬁcient
amount due to insulin deﬁciency resulting in hypertriglyceride-
mia [23]. The treatment with Polyherbal (PH), Allopolyherbal-
A (APH-A), Allopolyherbal-B (APH-B), and Allopolyherbal-
C (APH-C) formulations, led to a signiﬁcant decrease in total
cholesterol, triglycerides, LDL, and VLDL levels (Table 4),
which implies that these formulations can reduce the complica-
tions of lipidmetabolism and associated cardiovascular risk fac-
tors during diabetes. Allopolyherbal-C (APH-C) formulation
has proved to be most effective in improving lipid metabolism
in the present study as compared to Gliclazide.
Generally an increase in plasma serum creatinine levels is a
sign of impaired renal function; treatment with Polyherbal
(PH), Allopolyherbal-A (APH-A), Allopolyherbal-B (APH-
B), and Allopolyherbal-C (APH-C) formulations led to a
decrease in serum creatinine levels (Table 4), which shows im-
proved renal function.
Hepatotoxicity is another risk factor associated to oral
hypoglycemics on long term use. This risk factor can be mini-
mized by reducing the dose of oral hypoglycemics and using
them in combination with herbal drugs. The Polyherbal (PH)
and Allopolyherbal formulations (APH-A, APH-B, and
APH-C) exhibited better results than Gliclazide, for SGOT
and SGPT levels (Table 4).
Though Polyherbal and different Allopolyherbal formula-
tions showed maximum efﬁcacy for different biochemical
parameters, but looking to the results for all the parameters, it
may be concluded that Allopolyherbal-A formulation (APH-
A) was most effective in comparison to Polyherbal (PH), Allo-
polyherbal-B (APH-B), Allopolyherbal-C formulations, and
Gliclazide. There were no toxic effects during the 21 days of
study, regarding to hepatotoxicity and nephrotoxicity. So, the
Allopolyherbal-A formulation (APH-A) may be an ideal alter-
native for the existing hypoglycemic formulations with an addi-
tional advantage of hypolipidemic effect and minimizing the
cardiovascular risk factors associated with diabetes mellitus.5. Conclusion
The data suggest that the Polyherbal formulation and Allo-
polyherbal formulations exhibit signiﬁcant and consistent
R. Kumar et al.50hypoglycemic and Hypolipidemic along with improved hepatic
and renal function, in diabetic rats. Allopolyherbal-A formula-
tion (APH-A) has been proved to be most effective out of all
these formulations in improving the diabetic complications.
Therefore it may have beneﬁcial effects in type II diabetes mel-
litus and holds the hope of new generation oral hypoglycemic
drugs. A number of Polyherbal formulations are available in
the market for the treatment of diabetes like Diabegon,
Diabet, Glyoherb, Epinsulin, Diakyur, Dihar, Diashis, Diabe-
tica, Diacamp, Diavite, Glucocare, Glucotize, Gluconase, Sug-
armax, etc.
From the preceding results it can be concluded that the
Allopolyherbal-A formulation (APH-A) possesses the best
hypoglycemic and hypolipidemic actions along with improved
renal and hepatic functions. By using herbs with allopathic
drugs, the side effects of allopathic drugs can be minimized
with prolonged use. It was an effort to counteract or retard
the risk factors associated with diabetes mellitus by the use
of herbs along with allopathic drugs.
Since the dose of PH (3.63 g/kg body wt.) constituting the
Allopolyherbal formulation was on higher side so there is a
need for further extensive investigations, to decrease the dose
and prepare a suitable dosage form of Allopolyherbal-A for-
mulation (APH-A) that can be used as an effective oral hypo-
glycemic with an additional advantage of decrease in
complications associated to syndrome-X or it would be better
to use extracts of the respective plant part for the same.Acknowledgments
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